keyword
MENU ▼
Read by QxMD icon Read
search

cutaneous adverse effects, drug

keyword
https://read.qxmd.com/read/30720546/allergic-reactions-captured-by-voluntary-reporting
#1
Kimberly G Blumenthal, Anna R Wolfson, Yu Li, Claire M Seguin, Neelam A Phadke, Aleena Banerji, Elizabeth Mort
BACKGROUND: The epidemiology of hospital adverse reactions (ARs), particularly allergic reactions, or hypersensitivity reactions (HSRs), is poorly defined. To determine priorities for allergy safety in healthcare, we identified and described safety reports of allergic reactions. METHODS: We searched the safety report database of a large academic medical center from April 2006 to March 2016 using 101 complete, truncated, and/or misspelled key words related to allergic symptoms, treatments, and culprits (e...
January 31, 2019: Journal of Patient Safety
https://read.qxmd.com/read/30705309/nanoparticle-mediated-magnetic-hyperthermia-is-an-effective-method-for-killing-the-human-infective-protozoan-parasite-leishmania-mexicana-in-vitro
#2
Sarah L Berry, Karen Walker, Clare Hoskins, Neil D Telling, Helen P Price
Cutaneous leishmaniasis is a neglected tropical disease characterized by disfiguring skin lesions. Current chemotherapeutic options depend on toxic, expensive drugs that are both difficult to administer and becoming less effective due to increasing levels of resistance. In comparison, thermotherapy displays greater patient compliance and less adverse systemic effects, but there are still significant issues associated with this. The procedure is painful, requiring local anaesthetic, and is less effective against large lesions...
January 31, 2019: Scientific Reports
https://read.qxmd.com/read/30704945/-necrotic-leg-ulcers-after-topical-application-of-chlormethine
#3
C Gary, V Gautier, I Lazareth, M Bagot, R Asgari, P Priollet
BACKGROUND: Topical chlormethine has been widely used in the early stages of mycosis fungoides for many years. Cutaneous reactions (skin irritation and itch) are the most frequent adverse effects. Herein we report a rare side effect: severe necrotic leg ulcers. PATIENTS AND METHODS: An 82-year-old woman with a history of high blood pressure developed hyperalgesic necrotic ulcers on the lower limbs following local trauma one month after initiation of topical chlormethine (Valchlor® ) to treat mycosis fungoides...
January 28, 2019: Annales de Dermatologie et de Vénéréologie
https://read.qxmd.com/read/30681791/novel-tretinoin-0-05-lotion-for-once-daily-treatment-of-moderate-to-severe-acne-vulgaris-in-a-hispanic-population
#4
Fran E. Cook-Bolden, Susan H. Weinkle, Eric Guenin, Varsha Bhatt
Background: Acne vulgaris (acne) is the most common dermatologic disease seen in a racially, geographically, politically, culturally, and socioeconomically diverse Hispanic population. Despite their growing demographics in the US, there are few studies evaluating acne treatment in this population. Potential for skin irritation and dryness, as well as pigmentary changes are key concerns. The first lotion formulation of tretinoin was developed using novel polymerized emulsion technology to provide an important alternative option to treat these acne patients who may be sensitive to the irritant effects of other tretinoin formulations...
January 1, 2019: Journal of Drugs in Dermatology: JDD
https://read.qxmd.com/read/30681641/ocular-adverse-events-associated-with-mek-inhibitors
#5
Silvia Méndez-Martínez, Pilar Calvo, Oscar Ruiz-Moreno, Nieves Pardiñas Barón, Jesús Leciñena Bueno, María Del Rocío Gil Ruiz, Luis Pablo
PURPOSE: Mitogen-activates protein kinase (MAPK) inhibitors, particularly MEK inhibitors, have shifted the treatment paradigm for metastatic BRAF-mutant cutaneous melanoma; however, oncologists, ophthalmologists, and patients have noticed different toxicities of variable importance. This review aims to provide an update of the ocular adverse events (OAEs), especially retinal toxicity, associated with the use of MEK inhibitors. METHODS: We conducted a scientific literature search using the PubMed database up to July 2018 with the terms "MEK inhibitors" with a "review" filter and "MEK inhibitors" with a "clinical trials" filter...
January 23, 2019: Retina
https://read.qxmd.com/read/30681239/american-tegumentary-leishmaniasis-in-brazil-a-critical-review-of-the-current-therapeutic-approach-with-systemic-meglumine-antimoniate-and-short-term-possibilities-for-an-alternative-treatment
#6
Sílvia H Carvalho, Frédéric Frézard, Neila P Pereira, Alexandre S Moura, Lucinéia M Q C Ramos, Gabriel B Carvalho, Manoel O C Rocha
OBJECTIVES: Meglumine antimoniate (MA; Glucantime® ), the 80-year old first-line systemic treatment for all forms of American tegumentary leishmaniasis (ATL) caused by Leishmania (Viannia) braziliensis, L. (V.) guyanensis and L. (Leishmania) amazonensis, is highly toxic, presents adverse side-effects and may not attain clinical and parasitological cure. This critical review examines the necessity for intramuscular/intravenous administration of MA, the alternatives to this approach, and the possibilities of developing affordable, accessible and nontoxic drugs or new delivery methods...
January 25, 2019: Tropical Medicine & International Health: TM & IH
https://read.qxmd.com/read/30677804/pd-1-inhibitor-induced-alopecia-areata
#7
Jacqueline Guidry, Mariah Brown, Theresa Medina
Immune checkpoint modulators are becoming more prevalent in clinical use for the treatment of metastatic melanoma and other malignancies. These drugs, including programmed death 1 (PD-1) inhibitors, have a high incidence of immune adverse events, including cutaneous manifestations. Alopecia is a known side effect with these drugs, but previous reports describe chemotherapy-induced alopecia. We report a case of alopecia areata in a patient on monotherapy with pembrolizumab (PD-1 inhibitor). It is important for the dermatologist to recognize and appropriately treat to decrease morbidity for these patients...
December 15, 2018: Dermatology Online Journal
https://read.qxmd.com/read/30675173/dermatomyositis-associated-with-omalizumab-therapy-for-severe-asthma-a-case-report
#8
Samira Jeimy, Pari Basharat, Fiona Lovegrove
Background: Omalizumab is a humanized monoclonal antibody widely used for treatment of persistent allergic asthma and antihistamine-refractory chronic urticaria. Immediate adverse events to omalizumab are well characterized. Delayed anaphylactoid and serum sickness-like reactions have also been described; however, their relationship to the drug remains uncertain, and the frequency is unknown. Case presentation: We present a case of a 59-year old female who developed amyopathic dermatomyositis (DM) after receiving omalizumab infusions for steroid-refractory severe asthma...
2019: Allergy, Asthma, and Clinical Immunology
https://read.qxmd.com/read/30661315/eperisone-induced-anaphylaxis-pharmacovigilance-data-and-results-of-allergy-testing
#9
Kyung Hee Park, Sang Chul Lee, Ji Eun Yuk, Sung Ryeol Kim, Jae Hyun Lee, Jung Won Park
PURPOSE: Eperisone is an oral muscle relaxant used in musculoskeletal disorders causing muscle spasm and pain. For more effective pain control, eperisone is usually prescribed together with nonsteroidal anti-inflammatory drugs (NSAIDs). As such, eperisone may have been overlooked as the cause of anaphylaxis compared with NSAIDs. This study aimed to analyze the adverse drug reaction (ADR) reported in Korea and suggest an appropriate diagnostic approach for eperisone-induced anaphylaxis...
March 2019: Allergy, Asthma & Immunology Research
https://read.qxmd.com/read/30659806/potential-of-pluronics%C3%A2-p-123-and-f-127-as-nanocarriers-of-anti-leishmania-chemotherapy
#10
Jully Oyama, Daniele Stéfanie Sara Lopes Lera-Nonose, Áquila Carolina Fernandes Herculano Ramos-Milaré, Fabiana Borges Padilha Ferreira, Camila Fabiano de Freitas, Wilker Caetano, Noboru Hioka, Thaís Gomes Verzignassi Silveira, Maria Valdrinez Campana Lonardoni
Leishmaniasis is a neglected disease and drugs approved for its treatment often lead to abandonment, failure of therapy and even death. Photodynamic therapy (PDT) has been shown to be a promising, non-invasive and selective for a target region without requiring high-cost technology. Usually, it is employed a photosensitizing agent (PS) incorporated into nanoparticles (NP). Pluronics® P-123 and F-127 micelles are very interesting aqueous NP promoting efficient and selective delivery and less adverse effects...
January 16, 2019: Acta Tropica
https://read.qxmd.com/read/30649751/safety-and-tolerability-of-phosphatidylinositol-3-kinase-pi3k-inhibitors-in-oncology
#11
REVIEW
Giuseppe Curigliano, Rashmi R Shah
Activation of phosphatidylinositol-3-kinase (PI3K) and downstream signalling by AKT/mammalian target of rapamycin (mTOR) modulates cellular processes such as increased cell growth, cell proliferation and increased cell migration as well as deregulated apoptosis and oncogenesis. The PI3K/AKT/mTOR pathway (particularly Class I PI3K isoforms) is frequently activated in a variety of solid tumours and haematological malignancies, making PI3K an attractive therapeutic target in oncology. Inhibitors of PI3K also have the potential to restore sensitivity to other modalities of treatments when administered as part of combination regimens...
January 16, 2019: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://read.qxmd.com/read/30638600/allopurinol-induced-stevens-johnson-syndrome
#12
REVIEW
Sushilkumar Satish Gupta, Nitin Sabharwal, Ravikaran Patti, Yizhak Kupfer
Allopurinol is a first line agent in treating gout, but it also carries the risk of severe side effects. Stevens-Johnson syndrome (SJS) is one of the life threatening severe cutaneous adverse reactions caused by allopurinol. The severity of the severe cutaneous adverse reactions can be categorized based upon the area of skin involvement: (1) erythema multiforme major limited to 1-2 % of the body surface area (BSA); (2) SJS involving <10% of the BSA, (3) SJS and toxic epidermal necrolysis overlap involving 10-30% of the BSA and (4) toxic epidermal necrolysis syndrome involving >30% of the BSA...
December 4, 2018: American Journal of the Medical Sciences
https://read.qxmd.com/read/30614337/ixazomib-the-first-oral-proteasome-inhibitor
#13
Jingmei Xie, Ning Wan, Zhuoru Liang, Tiantian Zhang, Jie Jiang
Ixazomib, as a proteasome inhibitor, inhibits the chymotrypsin-like activity of the β5 subunit of the 20S proteasome. Based on the TOURMALINE-MM1 study, ixazomib was proved by the FDA as the orphan drug in November 2015. With a promising effect in prolonging the progression-free survival compared with placebo treatment (median: 20.6 versus 14.7 months), it was the first oral compound combined with lenalidomide and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) who have received at least one prior therapy...
January 7, 2019: Leukemia & Lymphoma
https://read.qxmd.com/read/30612984/markers-of-systemic-involvement-and-death-in-hospitalized-cancer-patients-with-severe-cutaneous-adverse-reactions
#14
Shoko Mori, Alanna Hickey, Stephen W Dusza, Mario E Lacouture, Alina Markova
BACKGROUND: Severe cutaneous adverse reactions (SCARs) are frequent in inpatient oncology. Early intervention may reduce morbidity, mortality, and hospitalization costs, however current clinical and histologic features are unreliable SCAR predictors. There is a need to identify rational markers of SCARs that could lead to effective therapeutic interventions. OBJECTIVE: To characterize the clinical and serologic features of hospitalized patients with cancer who developed SCARs...
October 26, 2018: Journal of the American Academy of Dermatology
https://read.qxmd.com/read/30601770/polycaprolactone-antimony-nanoparticles-as-drug-delivery-system-for-leishmaniasis
#15
Ariane de Jesus Sousa-Batista, Cristal Cerqueira-Coutinho, Fagner Santos do Carmo, Marta de Souza Albernaz, Ralph Santos-Oliveira
BACKGROUND: Leishmaniasis is a neglected disease endemic in tropical and subtropical areas, with an incidence about 1.6 million cases/year. The first-line treatment of this disease is pentavalent antimony, and the second-line are pentamidine and amphotericin B. All the treatments available cause severe side effects and often have difficulty in accessing parasites within infected cells. STUDY QUESTION: This study aimed to determine if the use of nanoparticles loaded with meglumine antimoniate could reach and targeting infected organs with leishmaniasis, reducing the dosage used and promoting less adverse effects...
January 2019: American Journal of Therapeutics
https://read.qxmd.com/read/30598499/adverse-event-management-in-patients-with-braf-v600e-mutant-non-small-cell-lung-cancer-treated-with-dabrafenib-plus-trametinib
#16
Anna Chalmers, Laura Cannon, Wallace Akerley
Therapies for advanced non-small cell lung cancer (NSCLC) continue to become more sophisticated. Chemotherapeutics are giving way to newer approaches such as immune checkpoint inhibitors and targeted therapies for greater efficacy and improved outcomes. Dabrafenib plus trametinib combination therapy was first approved for the treatment of metastatic melanoma harboring the BRAF V600-mutation in 2014. In 2017, the U.S. Food and Drug Administration approved the combination for patients with NSCLC with the same mutation based on an ≈ 65% response rate and median progression-free survival of 10-11 months...
December 31, 2018: Oncologist
https://read.qxmd.com/read/30597728/sterol-standardized-phytopharmaceutical-from-ground-cherry-corticoid-like-properties-on-human-keratinocytes-and-fibroblasts-and-its-effects-in-a-randomized-double-blind-placebo-controlled-clinical-trial
#17
Maria Del Carmen V Pereda, Gustavo Dieamant, Cecília Nogueira, Samara Eberlin, Gustavo Facchini, Lilian Mussi, Marcio A Polezel, Divino Martins-Oliveira, Paulo T V Rosa, Luiz C Di Stasi
BACKGROUND: Topical corticosteroids have been the most commonly prescribed drugs to treat skin inflammation, but their uses can lead to several adverse effects. Nowadays, new pharmacological strategies have been evaluated to improve dermatologic efficacy and reduce adverse effects, including natural products. OBJECTIVES: The aim of this study was to evaluate and compare the effects of a plant sterol standardized supercritical CO2 phytopharmaceutical of Physalis angulata L...
December 30, 2018: Journal of Cosmetic Dermatology
https://read.qxmd.com/read/30588271/bpx-01-minocycline-topical-gel-shows-promise-for-the-treatment-of-moderate-to-severe-inflammatory-acne-vulgaris
#18
Andrew Alexis, James Q Del Rosso, Seemal R Desai, Jeanine B Downie, Zoe Diana Draelos, Christina Feser, Rion Forconi, Joseph F Fowler, Michael Gold, Joely Kaufman-Janette, Edward Lain, Mark Lee, Mark Ling, Ava T Shamban, Wm Philip Werschler, Annamarie Daniels
Background and objectives: Acne vulgaris is a highly prevalent and multifactorial skin disorder that can adversely impact health-related quality of life. Factors that contribute to the pathogenesis of acne include pilosebaceous proliferation of proinflammatory Propionibacterium acnes ( P. acnes ) bacteria, presence of circulating androgens, excess sebum production, abnormal follicular keratinization, and multiple inflammatory cascades. Oral tetracyclines-especially doxycycline and minocycline-are frequently prescribed for the treatment of moderate-to-severe acne, given their anti-inflammatory properties and their effect on P...
November 2018: Journal of Clinical and Aesthetic Dermatology
https://read.qxmd.com/read/30539508/skin-reactions-to-immune-checkpoint-inhibitors
#19
Anisha B Patel, Omar Pacha
The novelty of immune checkpoint inhibitors has only recently led to the characterization of cutaneous adverse events (AEs). This, along with the substantial rate of cutaneous reactions, has left many clinicians without sufficient familiarity to diagnose and treat. Pruritus and rash are among the top five immune-related AEs reported in clinical trials for this class of therapy. Incidence varies between 35 and 50% for cutaneous AEs among the three FDA-approved drugs. Although only 2% are reported as grade 3 or 4 events, the quality of life impact can be significant for these patients and is best described in ipilimumab trials...
2018: Advances in Experimental Medicine and Biology
https://read.qxmd.com/read/30489484/subacute-cutaneous-lupus-erythematosus-induced-by-nivolumab-two-case-reports-and-a-literature-review
#20
Nesrine B Zitouni, Jean-Philippe Arnault, Ali Dadban, Christophe Attencourt, Catherine C Lok, Guillaume Chaby
Nivolumab is widely used to treat several late-stage malignancies such as melanoma and non-small-cell lung cancer by inhibiting the interaction between the programmed cell death protein-1 and its ligand. By stimulating an antitumor immune response, it also leads to immune adverse events. Here. we report two cases of subacute cutaneous lupus erythematosus (SCLE) induced by nivolumab. Case 1: a 72-year-old woman with a stage IV melanoma. Two months after nivolumab discontinuation because of autoimmune hepatitis, the patient was in complete remission and pruritic nummular erythematous plaques appeared on the back and arms...
November 26, 2018: Melanoma Research
keyword
keyword
109299
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"